644 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Why Lilly (LLY) Could Beat Earnings Estimates Again http://www.zacks.com/stock/news/547471/why-lilly-lly-could-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-547471 Oct 03, 2019 - Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Novartis Reports Additional Data on Spondylitis Drug Cosentyx http://www.zacks.com/stock/news/547460/novartis-reports-additional-data-on-spondylitis-drug-cosentyx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-547460 Oct 03, 2019 - Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.
Novartis (NVS) Announces Data on Asthma Drugs & Kisqali http://www.zacks.com/stock/news/545899/novartis-nvs-announces-data-on-asthma-drugs-kisqali?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-545899 Oct 02, 2019 - Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.
Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study http://www.zacks.com/stock/news/542832/pfizers-jak1-inhibitor-meets-all-goals-in-2nd-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542832 Sep 30, 2019 - Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.
IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA http://www.zacks.com/stock/news/539102/intelgenx-igxt-resubmits-nda-for-migraine-candidate-to-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-539102 Sep 27, 2019 - IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.
How Big Can This $8 Billion-Plus Diabetes Drug Class Get? https://www.fool.com/investing/2019/09/26/how-big-can-this-8-billion-diabetes-drug-class-get.aspx?source=iedfolrf0000001 Sep 26, 2019 - GLP-1 drugs keep getting easier to take.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/536794/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-536794 Sep 26, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Incyte Treats First Patient in Phase III Vitiligo Study http://www.zacks.com/stock/news/536926/incyte-treats-first-patient-in-phase-iii-vitiligo-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-536926 Sep 26, 2019 - Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.
AstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet http://www.zacks.com/stock/news/533723/astrazeneca-gets-chmp-nod-for-forxiga-onglyza-combo-tablet?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-533723 Sep 24, 2019 - The CHMP recommends AstraZeneca's (AZN) marketing application for Qtrilmet, a combination of Forxiga and Onglyza plus metformin, for treating patients with type-II diabetes.
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug http://www.zacks.com/stock/news/532222/ac-immune-to-earn-milestone-from-lilly-for-alzheimers-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-532222 Sep 23, 2019 - AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.

Pages: 123456789...65

<<<Page 4>